- PR Newswire•17 hours agoRegeneron and Sanofi to Present New Data on DUPIXENT® (dupilumab) for Moderate-to-Severe Atopic Dermatitis at Upcoming Medical Congresses
TARRYTOWN, N.Y. and CAMBRIDGE, Mass., Feb. 27, 2017 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that detailed results from the Phase 3 CHRONOS study will be ...
- PR Newswire•17 hours agoSanofi and Regeneron to Present New Data on Dupixent® (dupilumab) for Moderate-to-Severe Atopic Dermatitis at Upcoming Medical Congresses
CAMBRIDGE, Mass. and TARRYTOWN, N.Y., Feb. 27, 2017 /PRNewswire/ -- Sanofi and Regeneron Pharmaceuticals, Inc. today announced that detailed results from the Phase 3 CHRONOS study will be presented as a late-breaking abstract at this year's Annual Meeting of the American Academy of Dermatology (AAD). The CHRONOS study evaluated the use of investigational DUPIXENT for one year with topical corticosteroids versus topical corticosteroids alone for adults living with uncontrolled moderate-to-severe atopic dermatitis (AD). Additionally, interim safety and efficacy data will be presented from a Phase 3 long-term open-label study of DUPIXENT monotherapy for uncontrolled moderate-to-severe AD at the Annual Meeting of the American Academy of Asthma, Allergy, and Immunology (AAAAI).
- Investopedia•6 days ago
Amgen expects to launch the monthly-dose version of the cholesterol drug in the EU later this year.
REGN : Summary for Regeneron Pharmaceuticals, Inc. - Yahoo Finance
Regeneron Pharmaceuticals, Inc. (REGN)
NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
|Bid||351.00 x 100|
|Ask||373.05 x 100|
|Day's Range||359.93 - 373.30|
|52 Week Range||325.35 - 452.96|
Trade prices are not sourced from all markets
|PE Ratio (TTM)||48.45|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|